Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580928 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL), sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 4
- Study locations
NCT03580928 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 72 participants, below the 189-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (62% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03580928, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL), is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzmab
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Acalabrutinib
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Connecticut
- Stamford Hospital/Bennett Cancer Center - Stamford
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580928
The ClinicalTrials.gov registry entry for NCT03580928 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (62% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT03580928 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Connecticut, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT03580928 about?
NCT03580928 is a clinical study titled "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL". This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzmab
What is the current status of trial NCT03580928?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2018-08-07. Estimated completion is 2027-12-31.
What conditions does trial NCT03580928 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL).
What interventions are being tested in trial NCT03580928?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT03580928?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03580928 being conducted?
This trial has 4 study locations across Connecticut, Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.